Narnatumab  (Synonyms: IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab))

Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

RON(MSPR)^[1]

Narnatumab (100 nM; 24 h) inhibits MSP-induced migration of human lung and breast cancer cell lines^[1].
Narnatumab inhibits the MSP-induced mitogenic response of a pancreatic cancer cell line^[1].
Narnatumab (0.01-100 nM; pretreatment for 1 h) blocks ligand-induced receptor phosphorylation and downstream signaling molecules phosphorylation in RON-expressing tumor cells and in a RON-transfected cell line^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice^[1].
Narnatumab exhibits terminal half-life (t_1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1188275-92-4

[Narnatumab]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450.  [Content Brief]